A computational idea meets the laboratory

# A computational idea meets the laboratory OCTOBER 17, 2026 BioAge Labs and AI drug discovery company Deep Origin have launched a multi-target collaboration that already reached its first milestone: Deep Origin's software produced lab-confirmed drug hits against a new BioAge target in under three months. Financial terms were not disclosed beyond Deep Origin's eligibility for milestone payments. The useful moment in AI-assisted discovery is when a prediction survives contact with an experiment. The companies report an early example here, with the much longer development process still ahead. The companies announced the collaboration on October 14, 2026, according to Contract Pharma. BioAge is a clinical-stage company that develops treatments for cardiometabolic diseases by targeting the biology of human aging. Deep Origin supplies computational drug discovery. The first milestone is concrete. Deep Origin's platform delivered several structurally distinct small-molecule hits against the target. BioAge's wet lab then validated them. BioAge is now moving that target into hit-to-lead optimization, the stage where chemists refine early hits into more drug-like molecules. According to Contract Pharma, the collaboration relies on hybrid AI and physics-based models, which lets the companies focus on novel targets, meaning those with little known chemistry to start from. Deep Origin CEO Michael Antonov described the fit this way: "BioAge finds its targets in human data, from people followed for decades." He said many of those targets are novel, with little known chemistry, which is the problem Deep Origin's virtual screening was built to address. He also said BioAge set a high bar for the molecules its chemists would take forward. BioAge CEO Kristen Fortney said, "AI can help shorten the path from human biology to new medicines." She said the collaboration showed potential to speed early small-molecule discovery, and that BioAge looks forward to extending the work to additional targets. On the business side, Deep Origin is eligible for milestone payments based on the success of the collaboration. Contract Pharma did not report an upfront payment, a total deal value or how many targets are planned. Because those terms were not disclosed, readers should not assume there are no upfront or access fees, and the size of the commitment is hard to judge. For the market, the deal is a modest but useful data point. Many companies now sell AI-driven discovery, and the open question is whether it delivers usable starting molecules on hard, unprecedented targets. Milestone payments linked to the collaboration's success may suggest some confidence on both sides, but that is our reading, and the source does not say how the payments are set or what else Deep Origin is paid. Some caution applies. Hits are an early step. The announcement does not say whether any molecule will become a clinical candidate, and the timeline claim comes from the companies themselves. Early discovery speed matters only if later stages also succeed. WHAT TO WATCH NEXT Whether BioAge names additional targets under the agreement, and whether the first target produces optimized lead compounds from the hit-to-lead work. The next milestones will show whether the initial hits can become viable leads. Faster learning is valuable when each step produces evidence the next can use. Source: Contract Pharma ---